Back to search results

Salvaged Red Blood Cell Transfusion During Pancreatic Surgery

This study is looking at the safety of using your own salvaged red blood cells (sRBC) during pancreatic surgery. When you have surgery, some blood is lost. A special device called the Fresenius Kabi C.A.T.S®plus Continuous AutoTransfusion System collects this blood so it can be given back to you. Researchers want to see if this method causes fewer problems like infections (sepsis) or other issues compared to receiving donated blood. They will track any complications within 72 hours of surgery and for the first week afterward. You may be able to join if you are 18 or older and have been diagnosed with pancreatic cancer. The study aims to enroll 40 participants.

Study design
This interventional study plans to enroll 40 participants. It is designed to study the safety of using salvaged red blood cells during pancreatic surgery.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will follow participants for up to 7 days after surgery to track adverse events and transfusion-related complications.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07598357

Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations

Not Yet Recruiting
NAAges 18+Interventional
NYU Langone Health
~40 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:The Fresenius Kabi C.A.T.S®plus Continuous AutoTransfusion System

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of sepsis within 72 hours of operations
Measured over within 72 hours of operations
+2 more outcomes measured

Conditions

Pancreatic Surgery

Explore related trials

Pancreatic Adenocarcinoma

NCT07598357

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • NYU Langone Health

    New York, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Michael D. Kluger, MD, MPH · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Who to contact

Michael D. Kluger, MD, MPH
[email protected]
212-263-2630
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Rate of sepsis within 72 hours of operationswithin 72 hours of operations
  • Rate of transfusion related complication within the first 72 hoursUp to 7 days post-operative
  • Rate of all adverse events in the first post-operate weekUp to 7 days post-operative